---
schema_version: "secwatch.filing_event.v1"
accession: "0000875320-24-000012"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2024-02-05T23:59:59+00:00"
generated_at: "2026-06-06T09:35:51.644718+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Vertex Q4/FY23 revenue $2.52B/$9.87B; FY24 guidance $10.55-$10.75B; vanza triple and VX-548 NDAs by mid-2024

## Summary
- FY23 product revenue $9.87B (+11% YoY); Q4 revenue $2.52B (+9% YoY).
- FY24 product revenue guidance $10.55-$10.75B, reflecting CF growth and CASGEVY launch.
- Completed pivotal studies for vanzacaftor triple (CF) and VX-548 (acute pain); NDAs to FDA by mid-2024.
- CASGEVY approved in U.S., Great Britain, KSA, Bahrain; CHMP positive opinion; activated ATCs.
- VX-880 Phase 1/2 study on protocol-specified pause; VX-264 advanced to Part B.

## SEC filing metadata
- accession: 0000875320-24-000012
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2024-02-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532024000012/0000875320-24-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532024000012/vrtx-20240205.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875320-24-000012
- JSON: https://secwatch.observer/filing/0000875320-24-000012.json
- Plain text: https://secwatch.observer/filing/0000875320-24-000012.txt

## Key facts
- Earnings Releases
  VERTEX PHARMACEUTICALS INC / MA updated its the fourth quarter and full year ended December 31, 2023 guidance (raised).
  - Period: the fourth quarter and full year ended December 31, 2023
  - Guidance: raised
  - Result: reported results
  source text: On February 5, 2024, we issued a press release in which we reported our consolidated financial results for the three and twelve months ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/875320/000087532024000012/0000875320-24-000012-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.